Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
 |
Food and Drug Administration - September 28, 2005
Richard Klein, Kimberly StrubleOn September 28, 2005, The Food and Drug Administration approved EMTRIVA (emtricitabine) Oral Solution 10 mg/mL. The approval of this Oral Solution formulation allows for dosing recommendations in pediatric patients. EMTRIVA is now indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in patients over three months of age.
In addition the following changes to the label were made: (Please refer to the attached pdf document for specific details)
CLINICAL PHARMACOLOGY Section
Pharmacokinetic data in pediatrics, renal impairment information and results from a drug-drug interaction study with zidovudine were included.
INDICATIONS AND USAGE
The indication was expanded to include patients over three months of age.
PRECAUTIONS
Addition of zidovudine to the drug interactions section, addition of the immune reconstitution syndrome section, updated carcinogenicity data and pediatric use statements were included.
ADVERSE REACTIONS
This section was updated to include data in pediatric patients.
DOSAGE AND ADMINISTRATION
This section was revised to include dosing information in pediatric patients with the oral solution and capsule formulations. In addition, dosing information for the oral solution for adult patients was included. A new table was added to include dose adjustment information in adults with renal impairment for the capsule and oral solution formulations.
HOW SUPPLIED
Data on storage conditions for the Oral Solution were included.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
050928
FD050904
SOURCE: Food and Drug Administration (FDA).
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .